Respironics, Inc. (Nasdaq: RESP) today announced that it has formed an agreement with The State University of New York (SUNY) and New York University School of Medicine (NYU) to utilize the I-neb Adaptive Aerosol Delivery (AAD(R)) System for clinical evaluation of aerosolized Interferon Gamma for the treatment of Idiopathic Pulmonary Fibrosis (IPF). The clinical trial will take place over a two-year time period. [click link for full article]
(more...)